Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)Paulo M. Hoff, Mark Saunders, Brigitte Van Eyll et al.|Journal of Clinical Oncology|2012Cited by 154
Association of baseline CEA, VEGF, and soluble VEGF receptor-2 with treatment outcomes in two randomized phase III trials of cediranib in metastatic colorectal cancer (mCRC).Hans‐Joachim Schmoll, J.M. Jürgensmeier, P. M. Hoff et al.|Journal of Clinical Oncology|2011Cited by 7
Exploration of the effect of treatment to progression with the VEGF signaling inhibitor cediranib (CED) plus chemotherapy (CT) on the results of the HORIZON (HZ) II trial in first-line metastatic colorectal cancer.Anitra Fielding, Jane Robertson, P. M. Hoff et al.|Journal of Clinical Oncology|2011Cited by 3
Use of KRAS mutation status to predict clinical outcomes in patients with metastatic colorectal cancer (mCRC) treated with the VEGF signaling inhibitor cediranib.J.M. Jürgensmeier, Jeff Smith, P. M. Hoff et al.|Journal of Clinical Oncology|2011Cited by 3
Correlation of lactate dehydrogenase (LDH) isoenzyme profile with outcome in advanced colorectal cancer (CRC) patients (pts) treated with chemotherapy and bevacizumab (BEV) or cediranib (CED).Jair Bar, Glenwood D. Goss, Stuart Spencer et al.|Journal of Clinical Oncology|2012Cited by 1